<DOC>
	<DOCNO>NCT02533453</DOCNO>
	<brief_summary>As current study conduct provide additional information regard safety efficacy Bydureon , exenatide weekly injectable suspension , Korean population open label , non-comparative , multi-centre design use .</brief_summary>
	<brief_title>A 12/24-weeks , Open , Multi-centre , Phase IV Study Safety Efficacy 2mg Exenatide Once Weekly ( Bydureon ) T2DM Patients .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Male female , 1975 year age diagnose type 2 diabetes mellitus Patients achieve adequate glycaemic control maximally tolerate dose oral therapy ; Metformin Sulphonylurea Thiazolidinedione Metformin sulphonylurea Metformin thiazolidinedione Has treat , currently treat , expect require undergo treatment follow medication : 1 . Alpha glucosidase inhibitor meglitinide within 30 day screen ; 2 . Insulin within 2 week prior screen insulin longer 1 week within 3 month screen ; 3 . DPP4 inhibitor within 30 day screen ; 4 . Regular use ( &gt; 14 day ) drug directly affect gastrointestinal motility within 3 month screen ; 5 . Regular use ( &gt; 14 day ) systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary steroid know high rate systemic absorption within 3 month screen ; 6 . GLP1 receptor agonist except exenatide within 3 month screen ; diagnose type 1 diabetes mellitus diabetic ketoacidosis ; type 2 diabetes betacell dysfunction require insulin treatment Has ever use exenatide Pregnant breast feeding patient Hepatic disease ( defined aspartate alanine transaminase &gt; 3.0 time upper limit normal Endstage renal disease severe renal impairment ( creatinine clearance &lt; 30 ml/min )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus , T2DM , GLP-1 , GLP-1 Once weekly , Exenatide</keyword>
</DOC>